Daniel R Principe

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9266968/publications.pdf

Version: 2024-02-01

361413 276875 57 1,852 20 41 citations h-index g-index papers 57 57 57 3140 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	XP-524 is a dual-BET/EP300 inhibitor that represses oncogenic KRAS and potentiates immune checkpoint inhibition in pancreatic cancer. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119 , .	7.1	16
2	Loss of SMAD4 Is Associated With Poor Tumor Immunogenicity and Reduced PD-L1 Expression in Pancreatic Cancer. Frontiers in Oncology, 2022, 12, 806963.	2.8	14
3	The immune modifying effects of chemotherapy and advances in chemo-immunotherapy. , 2022, 236, 108111.		25
4	Blunt cardiac injury presenting as a left-sided coronary artery dissection. Journal of Surgical Case Reports, 2022, 2022, rjac008.	0.4	0
5	Intestinal adenocarcinoma originating from an undiagnosed Meckel's diverticulum. Journal of Surgical Case Reports, 2022, 2022, .	0.4	4
6	Precision Medicine for BRCA/PALB2-Mutated Pancreatic Cancer and Emerging Strategies to Improve Therapeutic Responses to PARP Inhibition. Cancers, 2022, 14, 897.	3.7	13
7	Inhibition of MNKs promotes macrophage immunosuppressive phenotype to limit CD8+ T cell antitumor immunity. JCI Insight, 2022, 7, .	5.0	7
8	Calcium channel blockers potentiate gemcitabine chemotherapy Âin pancreatic cancer. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, e2200143119.	7.1	14
9	Targeting Andâ€1 to overcome radiation resistance in colorectal cancer. Clinical and Translational Discovery, 2022, 2, .	0.5	O
10	Leukocyte subtyping predicts for treatment failure and poor survival in anal squamous cell carcinoma. BMC Cancer, 2022, 22, .	2.6	0
11	Patients deriving long-term benefit from immune checkpoint inhibitors demonstrate conserved patterns of site-specific mutations. Scientific Reports, 2022, 12, .	3.3	2
12	Preclinical Models of Pancreatic Ductal Adenocarcinoma and Their Utility in Immunotherapy Studies. Cancers, 2021, 13, 440.	3.7	27
13	Perforating duodenal ulcer with umbilical herniation as a metastatic complication of primary signet ring cell carcinoma of the breast. Journal of Surgical Case Reports, 2021, 2021, rjab034.	0.4	1
14	Trials and tribulations of pancreatic cancer immunotherapy. Cancer Letters, 2021, 504, 1-14.	7.2	37
15	Progress for Immunotherapy in Inflammatory Breast Cancer and Emerging Barriers to Therapeutic Efficacy. Cancers, 2021, 13, 2543.	3.7	4
16	Regulatory T-Cells as an Emerging Barrier to Immune Checkpoint Inhibition in Lung Cancer. Frontiers in Oncology, 2021, 11, 684098.	2.8	41
17	Glandular metastases from renal cell carcinoma show poor clinical responses to immune checkpoint inhibition but durable responses to angiogenesis inhibitors. BMJ Case Reports, 2021, 14, e243259.	0.5	2
18	HAI-1 is an independent predictor of lung cancer mortality and is required for M1 macrophage polarization. PLoS ONE, 2021, 16, e0252197.	2.5	5

#	Article	IF	CITATIONS
19	The Current Treatment Paradigm for Pancreatic Ductal Adenocarcinoma and Barriers to Therapeutic Efficacy. Frontiers in Oncology, 2021, 11, 688377.	2.8	82
20	MAP4K4 promotes pancreatic tumorigenesis via phosphorylation and activation of mixed lineage kinase 3. Oncogene, 2021, 40, 6153-6165.	5.9	19
21	Mixed Lineage Kinase 3 phosphorylates prolyl-isomerase PIN1 and potentiates GLI1 signaling in pancreatic cancer development. Cancer Letters, 2021, 515, 1-13.	7.2	12
22	$TGF\hat{I}^2$ Signaling in the Pancreatic Tumor Microenvironment. Cancers, 2021, 13, 5086.	3.7	27
23	Abstract PO-049: Inhibiting MNK kinases promotes macrophage immunosuppressive phenotype to limit anti-tumor immunity. , 2021, , .		0
24	Frequency and prognostic value of mutations associated with the homologous recombination DNA repair pathway in a large pan cancer cohort. Scientific Reports, 2020, 10, 20223.	3.3	15
25	Updated risk factors to inform early pancreatic cancer screening and identify high risk patients. Cancer Letters, 2020, 485, 56-65.	7.2	11
26	Metastatic Thymoma Harboring a Deleterious <i>BRCA2</i> Mutation Derives Durable Clinical Benefit from Olaparib. Oncologist, 2020, 25, 301-305.	3.7	9
27	Mitogen-Activated Protein Kinase Inhibitors and T-Cell-Dependent Immunotherapy in Cancer. Pharmaceuticals, 2020, 13, 9.	3.8	25
28	Chemotherapy-associated neutropenic enterocolitis of the transverse colon post right hemicolectomy. Oxford Medical Case Reports, 2020, 2020, omz140.	0.4	4
29	Long-Term Gemcitabine Treatment Reshapes the Pancreatic Tumor Microenvironment and Sensitizes Murine Carcinoma to Combination Immunotherapy. Cancer Research, 2020, 80, 3101-3115.	0.9	77
30	lleal carcinoid tumor represents after prolonged remission as a solitary breast mass. Journal of Surgical Case Reports, 2019, 2019, rjz171.	0.4	0
31	p $110\hat{1}^3$ deficiency protects against pancreatic carcinogenesis yet predisposes to diet-induced hepatotoxicity. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 14724-14733.	7.1	22
32	Repeat presentation of large rectal foreign body requiring surgical intervention. Journal of Surgical Case Reports, 2019, 2019, rjz121.	0.4	1
33	Non-implant associated primary cutaneous anaplastic large cell lymphoma of the breast. Journal of Surgical Case Reports, 2019, 2019, rjz139.	0.4	4
34	Cecum perforation secondary to plunger-induced barotrauma. Journal of Surgical Case Reports, 2019, 2019, rjz077.	0.4	2
35	TM4SF18 is aberrantly expressed in pancreatic cancer and regulates cell growth. PLoS ONE, 2019, 14, e0211711.	2.5	6
36	Massive adult cystic lymphangioma of the breast. Journal of Surgical Case Reports, 2019, 2019, rjz027.	0.4	6

#	Article	IF	CITATIONS
37	Combined radio-immunotherapy leads to complete clinical regression of stage IV Merkel cell carcinoma. BMJ Case Reports, 2019, 12, e230518.	0.5	4
38	Alveolar soft part sarcoma mimics prostate cancer metastasis. Oxford Medical Case Reports, 2019, 2019, 507-509.	0.4	1
39	TGFβ Blockade Augments PD-1 Inhibition to Promote T-Cell–Mediated Regression of Pancreatic Cancer. Molecular Cancer Therapeutics, 2019, 18, 613-620.	4.1	95
40	Of Mice, Dogs, Pigs, and Men: Choosing the Appropriate Model for Immuno-Oncology Research. ILAR Journal, 2018, 59, 247-262.	1.8	40
41	Loss of Sirt2 increases and prolongs a caerulein-induced pancreatitis permissive phenotype and induces spontaneous oncogenic Kras mutations in mice. Scientific Reports, 2018, 8, 16501.	3.3	13
42	Interplay between interferon regulatory factor 1 and BRD4 in the regulation of PD-L1 in pancreatic stellate cells. Scientific Reports, 2018, 8, 13225.	3.3	32
43	Genetically Induced Tumors in the Oncopig Model Invoke an Antitumor Immune Response Dominated by Cytotoxic CD8 $\hat{1}^2$ + T Cells and Differentiated $\hat{1}^3\hat{1}$ T Cells Alongside a Regulatory Response Mediated by FOXP3+ T Cells and Immunoregulatory Molecules. Frontiers in Immunology, 2018, 9, 1301.	4.8	15
44	KRASG12D and TP53R167H Cooperate to Induce Pancreatic Ductal Adenocarcinoma in Sus scrofa Pigs. Scientific Reports, 2018, 8, 12548.	3.3	23
45	The Complexity of Omega-3 Fatty Acid Modulation of Signaling Pathways Related to Pancreatic Cancer. Current Medicinal Chemistry, 2018, 25, 2608-2623.	2.4	8
46	The Oncopig Cancer Model: An Innovative Large Animal Translational Oncology Platform. Frontiers in Oncology, 2017, 7, 190.	2.8	92
47	A validated, transitional and translational porcine model of hepatocellular carcinoma. Oncotarget, 2017, 8, 63620-63634.	1.8	56
48	Loss of $TGF\hat{l}^2$ signaling promotes colon cancer progression and tumor-associated inflammation. Oncotarget, 2017, 8, 3826-3839.	1.8	34
49	SIRT2-Mediated Deacetylation and Tetramerization of Pyruvate Kinase Directs Glycolysis and Tumor Growth. Cancer Research, 2016, 76, 3802-3812.	0.9	92
50	$TGF\hat{l}^2$ Signaling in the Pancreatic Tumor Microenvironment Promotes Fibrosis and Immune Evasion to Facilitate Tumorigenesis. Cancer Research, 2016, 76, 2525-2539.	0.9	164
51	SIRT2 deletion enhances KRAS-induced tumorigenesis <i>in vivo</i> by regulating K147 acetylation status. Oncotarget, 2016, 7, 80336-80349.	1.8	35
52	HDAC3 mediates smoking-induced pancreatic cancer. Oncotarget, 2016, 7, 7747-7760.	1.8	41
53	PEDF inhibits pancreatic tumorigenesis by attenuating the fibro-inflammatory reaction. Oncotarget, 2016, 7, 28218-28234.	1.8	25
54	Activin and $TGF\hat{l}^2$ use diverging mitogenic signaling in advanced colon cancer. Molecular Cancer, 2015, 14, 182.	19.2	52

#	Article	IF	CITATIONS
55	Utilizing past and present mouse systems to engineer more relevant pancreatic cancer models. Frontiers in Physiology, 2014, 5, 464.	2.8	20
56	SIRT3 and SIRT4 are mitochondrial tumor suppressor proteins that connect mitochondrial metabolism and carcinogenesis. Cancer & Metabolism, 2014, 2, 15.	5.0	63
57	TGF-Â: Duality of Function Between Tumor Prevention and Carcinogenesis. Journal of the National Cancer Institute, 2014, 106, djt369-djt369.	6.3	413